Pay Blockchain Fees with Klever KDA Tokens 
HMM Announces Major Fleet Expansion to Boost Global Competitiveness 
Goobne Chicken Expands Its Global Presence with New Store in LA – It's 4th in the US 
Food Firms in Korea Such as Popeyes, Goobne Resume Price Hikes After Elections 
BMW Korea's Investment in S. Korean Suppliers of ₩6.63 Trillion Surpasses its Annual Revenue in the Country 
PUMA and Scuderia Ferrari Launch a New Era of Summer Fashion with Crews Go Summer Collection 
Adobe Unveils Acrobat AI Assistant Tool for Acrobat and Reader Users 
Introduction of Green License Plates in S, Korea Pull Down Sales of Porsche, Rolls Royce, Bentley 
SK on, Siemens Partner to Build Smart Factory System for Battery Plants 
Doosan Robotics, LG Electronics Debut EV Charging Robot, Kicks Off Pilot Operation in South Korea 
Xiaomi SU7 Offers Limited-Time Modification Service; Delivery Delays Extend to Six Months 
Burger King Launches New Whopper in South Korea After Chaotic Marketing Campaign 
An education in music makes you a better employee. Are recruiters in tune? 
PepsiCo Issues Recall for Schweppes Ginger Ale Over Sugar Content 
Tesla Reportedly Preparing for Large-Scale Layoffs; Employees Concerned Over Potential Termination 
The Nike Luka 3, Unveiled with Advanced Technology and Sustainability 
Naver and Shinsegae Group Ramp Up Strategies to Challenge Coupang 
SAN DIEGO, Nov. 08, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that the company will participate in the Stifel 2017 Healthcare Conference in New York, NY.
The Company will be presenting at 9:30 AM Eastern on Wednesday, November 15, 2017. A live webcast of the presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
